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Non-selective beta-blockers (NSBBs) are the mainstay of treatment for portal hypertension in the
setting of liver cirrhosis. Randomised controlled trials demonstrated their efficacy in preventing
initial variceal bleeding and subsequent rebleeding. Recent evidence indicates that NSBBs could
prevent liver decompensation in patients with compensated cirrhosis. Despite solid data favouring
NSBB use in cirrhosis, some studies have highlighted relevant safety issues in patients with end-
stage liver disease, particularly with refractory ascites and infection. This review summarises the
evidence supporting current recommendations and restrictions of NSBB use in patients with
cirrhosis.
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Almost 40 years ago, non-selective beta-blockers
(NSBBs) emerged in the field of cirrhosis and
portal hypertension (PH), as propranolol was
shown to prevent recurrent variceal bleeding.1 For
the following 3 decades, several randomised
controlled trials (RCTs) demonstrated the efficacy
of NSBBs for preventing primary and secondary
bleeding from oesophagogastric varices2–5 and
portal hypertensive gastropathy (PHG).6 Addi-
tionally, NSBBs reduce bacterial translocation and
the risk of spontaneous bacterial peritonitis (SBP),
and increase survival independent of bleeding
events.7,8 NSBBs have also been suggested to
decrease the risk of hepatocellular carcinoma.9
Interestingly, at the time of the first publication
in 1980, a letter alerted readers to potentially se-
vere hypotension induced by NSBBs in patients
with ascites related to their effect of on the renin-
angiotensin system.10 However, the tide began to
turn on NSBBs 30 years later when Sersté et al.
suggested that patients with refractory ascites on
NSBBs could have increased mortality.11 This has
led to a discussion on the safety of NSBBs in pa-
tients with ascites, infection or renal injury. Since
then, a plethora of mostly observational data
emerged and gave rise to the “therapeutic win-
dow” hypothesis, which questioned NSBB use in
early cirrhosis without medium-large varices and
cautioned to avoid them in patients with end-
stage liver disease and refractory ascites.12
This controversy has been tempered as more
recent and larger studies support the safety of
NSBBs in most indications, provided they are
used carefully. The scenario has been furtherchanged by the introduction of a new NSBB,
carvedilol, which has a greater effect on reducing
portal pressure than traditional NSBBs and has
significant clinical benefit in new indications in
compensated cirrhosis.13 However, data on how
well carvedilol is tolerated compared with
traditional NSBBs requires further assessment.
Furthermore, in the last 5 years, various studies
have demonstrated the safety and survival
benefit of NSBB use in decompensated cirrhosis,
putting into question some of the current
guideline recommendations.
Two systematic searches on Medline and
Embase were performed to assess i) the efficacy
of NSBBs in patients with cirrhosis and PH and ii)
the role of NSBBs on mortality in patients with
decompensated liver cirrhosis. This review aims to
provide a balanced summary of the existing evi-
dence on the indications for and the potential
limitations of beta-blockers in cirrhosis.
Brief overview of the pathophysiological
basis for using beta-blockers in cirrhosis
Portal venous pressure increases in the setting of
liver cirrhosis, first, due to increased resistance to
portal blood inflow at the hepatic circulation. This
has a mechanical component related to distortion
of liver microvascular architecture and a dynamic
component related to endothelial dysfunction,
which results in decreased availability of endog-
enous vasodilators, mainly nitric oxide (NO), and
increased release of vasoconstrictors (prosta-
noids, endothelins and angiotensin), leading to an
increased hepatic vascular tone. At a later stage,
portosystemic collaterals develop because ofbosch@idibaps.org (J. Bosch)
Key points
 Non-selective beta-blockers (NSBBs) are the established cornerstone
of treatment for prevention of first bleeding and rebleeding of oeso-
phageal varices in patients with cirrhosis.
 NSBBs include propranolol, nadolol, and timolol. Carvedilol is a new
NSBB that is increasingly used; it has a greater portal pressure
reducing effect than propranolol and is safe in patients with
compensated and decompensated cirrhosis.
 New trials should focus on NSBBs for the prevention of decompen-
sation (ascites) in compensated cirrhosis and prevention of mortality
and liver transplantation in decompensated cirrhosis.
 Fixed doses of NSBBs are discouraged. Rather, the dose should be
titrated individually. Adherence and doses of NSBBs should be reval-
uated whenever there are significant changes in the clinical condition
of the patient, especially low blood pressure.
 Refractory ascites, spontaneous bacterial peritonitis and acute-on-
chronic liver failure are not contraindications for NSBB treatment.
Doses should be carefully tapered, with a temporary reduction or
discontinuation in patients who develop signs of decreased organ
perfusion or significant hypotension. Re-initiation and titration of
NSBBs should be performed once the acute event is resolved.
Reviewdilatation of pre-existing vascular conduits caused by increased
portal pressure, as well as vascular endothelial growth factor-
mediated angiogenesis.14 This heralds splanchnic vasodilation
with increased blood inflow to splanchnic organs and the
portal system. Splanchnic vasodilation leads to systemic vaso-
dilation; the ensuing effective hypovolemia triggers expansion
of the plasma volume and increases the cardiac output. This
hyperkinetic circulation further increases the blood flow to
splanchnic organs, which contributes to an additional increase
in portal pressure.
The effects of NSBBs are summarised in Fig. 1. NSBBs, via
b1-adrenergic blockade, reduce heart rate and cardiac output
with a decrease in flow of about 20%. Whereas via b2-adrenergic
blockade, NSBBs cause splanchnic vasoconstriction due to un-
opposed adrenergic tone, with a subsequent additional decrease
in portal-collateral blood flow of about 15%, for a total 35%
reduction in portal venous inflow. This is the mechanism by
which NSBBs decrease the portal pressure by approximately
15%. Via an unopposed adrenergic tone, NSBBs cause a mild
increase in peripheral and hepatic resistance, which explains
why patients under NSBB do not develop arterial hypotension
and why the effect on portal pressure is relatively mild. Carve-
dilol is a NSBB that has an intrinsic anti-a1 adrenergic effect,
which causes intrahepatic vasodilatation and further decreases
portal pressure. Although carvedilol is more effective in
reducing hepatic venous pressure gradient (HVPG) than pro-
pranolol or nadolol, at relatively high doses (over 25 mg/d) it
may decrease mean arterial pressure (MAP).15 At low doses
(6.25–12.5 mg/d) carvedilol does not cause hypotension but
decreases portal pressure significantly more than propranolol.
Low doses cause only a moderate decrease in cardiac output and
heart rate. This could explain why carvedilol has been better
tolerated than therapeutic doses of propranolol, established

























Fig. 1. Pathophysiology of portal hypertension in cirrhosis and mechanisms
blocker.
JHEP Reports 2020Clinical benefit from NSBBs stems from a significant reduc-
tion in the portal pressure gradient, determined clinically at
hepatic vein catheterisation as the HVPG. The gradient must
decrease by at least 10% of baseline (preferably by at least 20%)
or below 12 mmHg to prevent first variceal bleeding (or liver
decompensation).16 To prevent rebleeding, it should drop by at
least 20% or below 12 mmHg.2,13,17–20 Although this is achieved
in about 50% of patients receiving propranolol,21 the proportion
of responders increases to about 75% when using carvedilol
(even in propranolol non-responders).19
Satisfactory responses to NSBBs are associated with a
decreased risk of bleeding, as well as a lower risk of ascites, SBP,























and sites of action of non-selective beta-blockers. NSBB, non-selective beta



















































































Indications for beta-blockers in cirrhosis: levels of evidence and grade of recommendation
Fig. 2. Levels of evidence for non-selective beta-blockers in cirrhosis according to indication. CSPH, clinically significant portal hypertension;
GOV1-2, gastroesophageal varices type 1/2; IGV1, isolated gastric varices type 1; NSBB, non-selective beta blocker; RCT, randomised controlled trial.reflecting a favourable impact on the natural history of the
disease; this is one of the advantages of NSBBs compared to
endoscopic therapy. The level of evidence for NSBB use in the
main indications of cirrhosis is summarised in Fig. 2.Indications
Prevention of first variceal bleeding (primary prophylaxis)
Patients with high-risk varices and compensated cirrhosis
Currently, NSBBs and endoscopic band ligation (EBL) are consid-
ered equally effective in preventing first bleeding in patients with
high-risk varices,22–24 i.e.medium to large varices or small varices
with red wale marks or in patients with decompensated cirrhosis
(Child-Pugh B/C).22,25 NSBBs are favoured over endoscopic ther-
apy in patients with small, high-risk varices, given the size of the
varices.22
In patients with compensated cirrhosis and high-risk varices,
the primary goal of therapy is not limited to bleeding preven-
tion (that is not the most common event), but must also focus
on preventing decompensation of cirrhosis (ascites, variceal
bleeding or hepatic encephalopathy). However, the vast major-
ity of studies were only designed to evaluate reductions in the
risk of haemorrhage and subsequent bleeding-related death.
Moreover, most studies included both compensated and
decompensated patients. As stated above, it is now preferred to
consider therapy according to the stage of the disease; treating
compensated patients to prevent decompensation and decom-
pensated patients to prevent liver transplantation and death.
Considering this, pharmacological therapy may be a better
approach than endoscopic treatment, given its ability to prevent
decompensation. It is well known that ascites may be prevented
in haemodynamic responders to NSBBs,13 while this is not
possible with endoscopic treatments.
NSBBs are effective in preventing first bleeding event in pa-
tients with cirrhosis, independent of disease severity.26 In 1999,
a meta-analysis of RCTs selected 8 studies including patients
with medium-large varices. This meta-analysis compared NSBBs
(propranolol/nadolol) to placebo or nonactive treatment and
demonstrated a clear reduction in absolute risk of bleeding and
bleeding-related mortality, but not overall mortality.27 TheJHEP Reports 2020absolute risk reduction of first variceal haemorrhage within
2 years of follow-up was −10% in patients with NSBBs vs. pla-
cebo. A small decline in absolute mortality rate, of −4% was
found, approaching statistical significance. When the analysis
was stratified to patients with high-risk varices, the bleeding
rate in treated patients diminished significantly, by −16%.27
In 2012, a meta-analysis of 19 trials suggested that EBL was
slightly superior to NSBBs for primary prophylaxis of variceal
bleeding (risk ratio [RR] 0.67; 95% CI 0.46–0.98; p = 0.037).
However, on further analysis, no significant differences were
found either in bleeding-related or overall mortality compared
with NSBBs in high-quality trials. Complications or side effects
associated with EBL are less frequent, but more severe and
potentially fatal.28,29
Regarding carvedilol, the first RCT comparing carvedilol to
EBL30 reported that carvedilol had lower rates of the first variceal
bleed (10% vs. 23%, p = 0.04), with no significant differences in
overall mortality (35% vs. 37%, p = 0.71), and bleeding-related
mortality (3% vs. 1%, p = 0.26), but did not report data on other
events. Thirty percent of patients in both arms dropped out and
per-protocol analysis revealed no significant differences in out-
comes; in addition, the study was underpowered. Another study
showed that, in propranolol non-responders, carvedilol could
effectively decrease HVPG; during a 2-year follow-up, bleeding
rates for propranololwere 11% compared to 5%with carvedilol and
25% with EBL (p = 0.04).19 A further trial in Pakistan showed that
both EBL and carvedilol monotherapy groups had comparable
variceal bleeding (8.5% vs. 6.9%), bleeding-related mortality (4.6%
vs. 4.9%) and overall mortality rates (12.8% vs. 19.5%), respec-
tively.31 An additional study comparing EBL vs. propranolol and
carvedilol showed comparable rates of bleeding prevention.32
Again, these studies provide no data on prevention of other com-
plications of PH. Presently, there is still insufficient data showing
superiority of either EBL or carvedilol therapy in primary preven-
tion of bleeding. The ongoing CALIBRE multicentre UK trial is
designed to compare carvedilol to EBL inprevention of bleeding.33
These results are awaited, particularly regarding impact on pre-
venting other liver-related complications.
A network meta-analysis using data combining direct and
indirect evidence from 32 RCTs including 3,362 patients with3vol. 2 j 100063
Reviewcirrhosis with high-risk varices assessed the effect of different
treatment modalities on first episode of variceal bleeding
and mortality. Regarding bleeding prevention, on direct meta-
analysis, EBL monotherapy reduced the risk of first variceal
bleed compared to placebo (odds ratio [OR] 0.36; 95% CI
0.14–0.92), to NSBB (OR 0.52; 95% CI 0.35–0.78), and to iso-
sorbide mononitrate (ISMN) (OR 0.25; 95% CI 0.07–0.93). EBL
monotherapy was associated with a higher risk of overall
mortality compared with NSBBs, although not significant (OR
1.35; 95% CI 0.98–1.86). Side effects were more common with
NSBBs, leading to 10–13% rates of treatment discontinuation,
but almost all of the serious adverse events were related to
EBL.34 Six RCTs within this meta-analysis compared combined
EBL or ISMN and NSBBs to monotherapy and demonstrated
that combination therapy significantly reduced first variceal
bleeding compared with placebo (OR 0.34; CI 0.14–0.86).
However, in the trials of combined therapy, adverse events were
reported in 59% of patients receiving a combination of EBL and
NSBBs, in 51% of patients receiving carvedilol monotherapy and
ranged between 20–24% for those receiving other NSBBs or EBL
or ISMN or combined NSBB+ISMN.34 The 2 existing trials on
combined endoscopic and NSBB therapy vs. monotherapy
showed no added benefit.7,35 In 2017, a multicentre RCT from
Korea reported that propranolol + EBL was more effective for
primary prophylaxis in patients with high-risk varices. More-
over, combination therapy was more effective in the prevention
of variceal recurrence after EBL eradication. Adverse event rates
were not described.36 It is still unclear whether combination
therapy is more effective and safer for primary prophylaxis.
Although current guidelines recommend either NSBBs or EBL as
equivalent therapies for primary prophylaxis, recent evidence
shows that NSBBs in patients with compensated cirrhosis and
clinically significant portal hypertension (CSPH) can prevent
first decompensation, namely ascites. Thus, since EBL is not
likely to prevent ascites, NSBBs are emerging as the preferred
option.13
Patients with high-risk varices and decompensated cirrhosis
The potential limitations of NSBBs in end-stage cirrhosis will
be discussed later in a dedicated section. There is firm data
supporting NSBB use in the prevention of first variceal
bleeding event in both patients with and without ascites. An
individual patient meta-analysis of 4 RCTs showed that NSBBs
effectively prevent the first episode of variceal bleeding and
reduce bleeding-related mortality independently of cirrhosis
stage.26 The 2-year bleeding rate was reduced by 9%. The risk
decrease was observed in patients with ascites (−14%) and
without ascites (−15%). According to the log-rank test on
Kaplan-Meier cumulative estimates, the reduction in first
bleeding episode was statistically significant (from 41% to 27%,
p = 0.002).26,27
Furthermore, a meta-analysis on prevention of first bleeding
and rebleeding analysed both patients with cirrhosis with and
without ascites, who responded to treatment with NSBB (based
on reductions in HVPG), and demonstrated a reduced risk of
liver-related events, death, or liver transplantation.37
Following 2 observational studies, concerns regarding beta-
blocker use in the context of ascites11 or SBP38 were raised.
Since then, various studies questioned the validity of the find-
ings and showed that in decompensated patients NSBB use
improved survival39–43 or showed no difference.41 A retrospec-
tive study of 264 propensity score matched patients underJHEP Reports 2020carvedilol use and decompensated cirrhosis, showed increased
survival in the carvedilol group vs. non-carvedilol groups
(24% vs. 2%, p <0.0001). The long-term survival was significantly
better in the carvedilol than the non-carvedilol group (log-rank
p <0.001).44
Prevention of the formation or growth of varices
(preprimary prophylaxis)
Patients with no varices or non-high-risk varices and compensated
cirrhosis
Presently, there is not enough evidence to support the use of
NSBBs to prevent the development or growth of varices in pa-
tients with cirrhosis without varices or with small varices
without red wale signs. One French study evaluated the effect of
propranolol on preventing the development of large oesopha-
geal varices over 2 years in patients with or without small
varices.45 More than twice the patients assigned to propranolol
developed varices compared to placebo, but one-third of the
patients were lost to follow-up, in addition to those who sus-
pended therapy because of intolerance. Bleeding and mortality
rates were similar. A multicentre, single, double-blind RCT of
timolol vs. placebo showed that, after 55 months, 39% and 40%
of patients in the timolol and placebo groups, respectively,
developed varices. Additionally, adverse events were more
frequent in the timolol group. However, the study disclosed that
the development of large varices, variceal bleeding, ascites,
encephalopathy, and death did not occur when HVPG remained
below 10 mmHg, and that varices developed much less
frequently when HVPG was decreased by over 10% of baseline.
A therapeutic benefit of timolol in preprimary prophylaxis
could not be established.46 Among possible causes are sample
size distribution and inclusion of patients without CSPH (HVPG
<10 mmHg). Around 50% of the patients did not have CSPH and,
thus, had not fully developed a hyperdynamic circulatory state.
At this stage, the effect of propranolol on portal pressure has
been shown to be almost negligible.47
More recently, Sarin et al. showed that in patients with
cirrhosis and small oesophageal varices, NSBBs were unable to
prevent the growth of varices, variceal haemorrhage, or mor-
tality.48 In contrast, 2 studies showed evidence in favour of beta-
blockers to delay growth of small varices. One RCT comparing
nadolol to placebo reported cumulative risks of variceal pro-
gression in 20% vs. 51%, for the nadolol and placebo groups,
respectively. The cumulative probability of variceal bleeding
was also lower in patients randomised to nadolol (p = 0.02).
Survival was not different and adverse effects resulting in
withdrawal were more common in the nadolol group.49 Car-
vedilol was tested in another RCT against placebo to assess the
delay in small varices progression; this study showed that 79%
of patients in carvedilol group vs. 61% of patients in placebo
group were free from progression to large varices (p = 0.04).
No differences were found regarding bleeding events, mor-
tality or adverse side effects.50 A meta-analysis of 6 RCTs
including patients with no or small varices found no signifi-
cant benefit for NSBBs compared to placebo for the prevention
of large varices, first variceal bleeding and death.51 Overall, the
evidence is conflicting regarding an impact of beta-blockers on
slowing the progression of small varices to large varices in
patients with cirrhosis. At this stage, treatment should be
centred on eliminating or controlling the cause of liver disease
to attempt regression of architectural changes and reduction
of intrahepatic resistance. Furthermore, it is currently accepted4vol. 2 j 100063
that at such an early stage, treatment in patients with
compensated cirrhosis should be aimed at preventing a first
episode of clinical decompensation, the most frequent being
ascites.
Prevention of decompensation
Data from trials demonstrating the effect of NSBBs on the pre-
vention of clinical decompensation were non-existent. Previous
trials illustrated that decompensation risk was concentrated
almost exclusively in patients with a baseline HVPG >−10 mmHg,
the threshold defining CSPH.52 Moreover, patients with CSPH
exhibit a greater HVPG response to NSBBs than those without,
suggesting that NSBBs may be an effective option to prevent
decompensation, and that compensated patients with CSPH, but
without high-risk varices, would be the ideal population to test
this hypothesis.
The PREDESCI trial, a multicentre, double-blind, RCT adop-
ted this set-up and investigated whether long-term treatment
of patients with compensated cirrhosis and CSPH with NSBBs
might prevent progression to clinical decompensation or death.
Patients developing moderate-large varices in both arms
received EBL. This is the first RCT to show that long-term
treatment with NSBBs decreases clinical decompensation or
liver-related death by half. This was mainly due to decreased
rates of ascites, which is the most common decompensating
event and for which there was previously no effective pre-
ventive drug therapy. There were no differences in the bleeding
incidence in the study, probably due to the use of EBL in pa-
tients developing high-risk varices. One likely explanation is
that the study showed that NSBBs, but not placebo, signifi-
cantly reduced the HVPG at each yearly control, and that re-
ductions of at least 10% from baseline or to below 10 mmHg
conferred marked protection from decompensation and death
during follow-up.13
Prevention of rebleeding and death (secondary prophylaxis)
The main goal of treating patients with cirrhosis after an acute
variceal haemorrhage, as first decompensating event, has
been to prevent recurrent variceal bleeding. However, these
patients very frequently show additional manifestations of
decompensation, such as ascites or hepatic encephalopathy,
and have a poor prognosis. Thus, since Baveno VI, the aim of
therapy in these cases should be liver transplantation and
death prevention, while decreasing further decompensation
rates would represent a secondary endpoint. Nonetheless, to
date, trials have aimed primarily at recurrent variceal
bleeding prevention, so the available data on outcomes, as per
Baveno VI, are limited. Baveno VI recommends a combination
of NSBBs (propranolol or nadolol) and EBL for rebleeding
prevention.22
A meta-analysis of 12 RCTs comparing NSBBs vs. placebo
showed a mean absolute reduction of rebleeding of 21% in the
NSBB group.53 Nine RCTs comparing propranolol and sclero-
therapy were analysed. Sclerotherapy was more effective in
preventing variceal rebleeding, but with significantly higher
adverse event rates, and no difference in survival rates.53 In a
meta-analysis, the combination of NSBBs and low-dose ISMN
was not significantly better than NSBBs alone, but had a higher
rate of adverse events.54 In 2012, a meta-analysis of 9 trials
assessed the effects of EBL plus NSBBs±ISMN vs. monotherapy
(EBL or NSBBs±ISMN) for secondary prevention of recurrent
bleeding. Combination therapy reduced mortality related toJHEP Reports 2020rebleeding (RR 0.52; number needed to treat = 33) and the risk
of recurrent bleeding from oesophageal varices (RR 0.68;
number needed to treat = 8).9
Four trials comparing drugs alone (NSBB+ISMN) or associ-
ated with EBL, including 409 patients, demonstrated that vari-
ceal rebleeding decreased with combined therapy (p <0.01), but
rebleeding from oesophageal ulcers increased (p = 0.01). Overall,
there was a trend towards lower rebleeding (RR 0.76; 95% CI
0.58–1.00) without significant effects on mortality (RR 1.24; 95%
CI 0.90–1.70). Combination therapy (NSBB+ISMN) was only
slightly more effective than drug monotherapy.55 An individual
patient data meta-analysis of 7 trials comparing combined EBL +
NSBB vs. monotherapy (either NSBBs or EBL) showed that
compared with EBL alone, EBL + NSBB reduced rebleeding in
both Child-Pugh A and B/C patients, with a significant reduction
in mortality in Child-Pugh B/C patients (incidence rate ratio
[IRR] 0.46; 95% CI 0.25–0.85), whereas NSBBs alone performed
as well as combination therapy. This study highlighted the in-
dependent role that NSBBs play in modifying survival, particu-
larly in patients with advanced liver failure (Child-Pugh B/C).56
Thus, it has been suggested that patients with contraindica-
tions or who cannot tolerate NSBBs should be considered for
transjugular intrahepatic portosystemic shunt (TIPS), particu-
larly in the presence of another indication, i.e. difficult to treat or
refractory ascites.
Regarding carvedilol, 1 trial compared the safety and efficacy
of carvedilol to nadolol plus ISMN in preventing variceal
rebleeding. The treatments were equally effective with similar
mortality rates, but the carvedilol group had significantly less
adverse events (3% vs. 46%, p <0.0001).57 A multicentre RCT with
64 patients compared carvedilol and EBL and reported no dif-
ference for rebleeding and a trend towards reduced mortality
for carvedilol (27% vs. 52%, p = 0.110).58 More recently, a meta-
analysis compared the efficacy and safety of carvedilol plus
EBL vs. traditional NSBBs plus EBL in preventing variceal
rebleeding. Carvedilol decreased rebleeding rates (p <0.001) and
drug-related adverse events (p <0.001) more than traditional
NSBBs. No difference was noted with respect to mortality.
Nevertheless, these findings must be interpreted cautiously
given the overall suboptimal quality of the eligible studies and
the lack of HVPG.59
Gastric and ectopic varices
Gastric and ectopic varices are particularly more frequent in
presinusoidal PH compared to patients with cirrhosis. Thus,
RCTs are scarce and include small samples and patients with
differing disease states: either with or without cirrhosis, or with
gastric and oesophageal varices. Therefore, the degree of evi-
dence is much less firm than in patients with cirrhosis.
Gastroesophageal varices type 1 (GOV1) are the most com-
mon (around 75% of gastric varices) and are oesophageal varices
extending below the cardia into the lesser curvature. These are
most frequently associated with bleeding, although less severe
than cardiofundal variceal bleeding, and are managed like
oesophageal varices.22 GOV type 2 (GOV2) extend to the fundus
and tend to be longer and more tortuous. Isolated gastric
varices type 1 (IGV1) are located in the fundus, while IGV type 2
are found elsewhere in the stomach. Cardiofundal varices
(GOV2 and IGV1) bleed less frequently, but are generally more
severe, more difficult to control and show a higher risk of
bleeding recurrence and mortality compared to oesophageal
varices.60,615vol. 2 j 100063
ReviewPrevention of first bleeding
The 2 most widely used treatments in this context are NSBBs
and endoscopic variceal obliteration with tissue adhesive in-
jection. Solid data from RCTs is too scarce to demonstrate su-
periority of cyanoacrylate variceal obliteration over NSBBs. One
RCT reported a higher rate of first bleeding episodes in patients
with cardiofundal varices (GOV2 and IGV1) in the group treated
with NSBBs compared to cyanoacrylate injection (38% vs. 10%,
p = 0.003), with similar survival rates (83% vs. 74%, p = 0.113).62
Guidelines advocate NSBBs for primary bleeding prophylaxis of
GOV2 and IGV1 based on a potential lower risk of complications
and the possibility of clinical decompensation prevention. GOV1
varices should be treated per guidelines for oesophageal varices
(either NSBBs or EBL).22,23
Management of acute bleeding and prevention of rebleeding
Medical treatment of acute bleeding from gastric varices is
similar to oesophageal varices, except that the preferred
endoscopic therapy for gastric varices is variceal obliteration
with endoscopic cyanoacrylate injection.23 Assessment is
complicated by the fact that many studies have small samples
and include patients with GOV1 varices and different aetiol-
ogies of PH, including some patients with extrahepatic portal
vein occlusion or idiopathic PH. A single RCT with 95 patients
concluded that adding NSBBs provided no additional benefit to
obliteration with cyanoacrylate for the prevention of rebleeding
and mortality.63 Nevertheless, the study was powered to assess
a 25% absolute decrease in risk of rebleeding, so a smaller
reduction in absolute risk of bleeding could not be ruled out.
One small trial compared TIPS to cyanoacrylate injection in 72
patients; TIPS proved more successful in preventing rebleeding
from gastric varices, without significant differences regarding
survival and adverse events.64 However, TIPS might not be
possible in some of the patients with extrahepatic portal vein
occlusion. In these cases, other forms of percutaneous radio-
logical intervention procedures, such as balloon-occluded
retrograde transvenous obliteration of gastric varices, and var-
iants of the technique, may be lifesaving. However, a detailed
discussion of these procedures is beyond the scope of the cur-
rent review.
Bleeding from ectopic varices is very rare in cirrhosis, but is
more frequent in patients with extrahepatic portal vein occlu-
sion, overall representing between 1 and 5% of all gastrointes-
tinal haemorrhage in patients with PH.65–67 Ectopic varices are
dilated portovenous vessels located outside of the oesophagus
or the stomach. Anatomic mapping is essential and the het-
erogeneity in localisation limits the implementation of standard
treatment. Current treatment options include endoscopic ther-
apy, mostly with cyanoacrylate injection or endosonographic
coil placement, TIPS with or without embolisation, and balloon-
occluded retrograde transvenous obliteration.24 There is no data
from controlled trials assessing the role of NSBBs in patients
with ectopic varices.
Portal hypertensive gastropathy
Data is lacking regarding beta-blockers for primary prophylaxis
of bleeding from PHG.68 Two previous studies demonstrated a
reduced risk of PHG in patients under NSBBs compared to those
treated only with EBL for bleeding prophylaxis.69,70 One study
compared carvedilol vs. propranolol vs. EBL for primary pre-
vention of variceal bleeding, and studied the effect of each
treatment on PHG after 1 year. The carvedilol and propranololJHEP Reports 2020groups had a lower risk of PHG compared to those under
endoscopic therapy.32
In patients with previous acute or chronic bleeding, the
benefit of beta-blockade is more established. Current guidelines
recommend NSBBs as first line therapy in preventing recurrent
bleeding from PHG.22 An RCT in patients with cirrhosis and PHG
reported PHG-associated rebleeding rates of 65% in controls
vs. 38% in patients under propranolol (doses 40–320 mg/d)
(p <0.05). At 30 months, over 50% of patients on propranolol did
not experience rebleeding compared to less than 10% of con-
trols.6 An earlier, smaller study involving 38 patients with PHG
(14 with acute bleeding and 24 with nonbleeding PHG)
described a decrease in the incidence of rebleeding and a
reduction in PHG with propranolol.71
Acute bleeding associated with PHG is rare. A multicentre
study reported a 2.5% rate of acute PHG-related bleeding during
a mean follow-up period of 18 months.72 The evidence sup-
porting NSBBs during bleeding events is very scarce.71 Current
guidelines advocate beta-blockers for secondary prophylaxis
after adequate bleeding control with faster-acting vasoactive
drugs.22Beta-blocker contraindications, dosage and side
effects
Contraindications and dosage
Absolute or relative contraindications for NSBBs are present in
around 15% of patients because of coexisting conditions and, in
another 15%, dose reduction or withdrawal may be necessary
because of adverse effects73 (Box 1). These limitations should
not discourage patients and clinicians from using NSBBs for the
indications previously described, given the firm evidence of
their efficacy in cirrhosis and PH (Table 1).
Although limited data shows that there is no correlation
between the decrease in HVPG and a decrease in heart rate,74
current clinical practice recommends an approximate 25%
decrease in heart rate as evidence of adequate beta-adrenergic
blockade with NSBBs. It is usually advised that NSBBs be
titrated until the maximum tolerated dose, provided the sys-
tolic blood pressure remains above 90 mmHg and heart rate
above 55 bpm. Specific data on titration, frequency of
administration, and maximum doses for each NSBB are pro-
vided in Table 2. Once started, NSBBs should be maintained for
life. According to Baveno I-VI, no endoscopic surveillance is
required once patients have achieved a stable maintenance
dose.
Side effects
NSBBs can have a negative impact on a patient’s quality of life.
This is mainly due to adverse effects such as worsening fatigue,
reduced exercise capacity and sexual dysfunction. These
symptoms are unspecific and can be attributed to cirrhosis or
depression. Therefore, dose reduction or switch to another NSBB
(for instance, carvedilol if the patient was on propranolol or
nadolol) is recommended rather than discontinuing therapy.
After initiating NSBBs, they should be revaluated periodically as
intolerance or contraindications can develop later on. It is
currently unknown which threshold of blood pressure and/or
heart rate and cardiac output reduction can be considered safe,
particularly in patients with decompensated cirrhosis. Specific
studies examining this issue are warranted, although it is clear
that adverse events are dose related. Table 2 indicates the dose6vol. 2 j 100063
Box 1. Non-selective beta-blocker contraindications and adverse effects.
Absolute contraindication
Second-or third-degree AV block (in the absence of a permanent pacemaker)






Uncontrolled diabetes mellitus and hypoglycemia
Raynaud syndrome
Consider reducing the dose or discontinuing the NSBB
Hypotension (systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg)
Development of acute kidney injury/ hepatorenal syndrome
Hyponatremia (serum sodium <130 mEq/L)





Gastrointestinal symptoms (nausea, constipation)
Sexual and erectile dysfunction
AV, atrioventricular; NSBB, non-selective beta-blocker.limits for each beta-blocker. Furthermore, since propranolol is
exclusively metabolised by the liver, the dose should be reas-
sessed for tolerance when liver failure progresses in a given
patient.Potential limitations
Ascites and refractory ascites
In an observational study, Sersté et al. questioned the use of
NSBBs in 151 patients with advanced cirrhosis and suggested
that NSBBs decreased survival in patients with refractory asci-
tes.11 However, a more severe underlying liver disease, higher
bilirubin, lower serum sodium, higher prevalence of Child-Pugh
class C, and higher prevalence of high-risk varices in the group
with NSBBs might justify these differences. Subsequent studies
provided evidence on the safety of NSBBs for patients with
refractory ascites.39,40,44,75–80 The deleterious effect of NSBBs
reported by Sersté et al.11,81 could also have been related to high
doses of propranolol: nearly half of the patients were receiving
160 mg/d (and 7 out of 10 patients in the consecutive crossover
study). A nationwide study based on Danish registers evaluated
3,719 patients with cirrhosis and ascites. Propranolol doses
>160 mg/d were associated with higher mortality than doses
<160 mg/d.40 Since propranolol is metabolised exclusively by
the liver, its dose should be restricted in advanced cirrhosis.
These patients should probably not receive propranolol doses
>80 mg/d.78 As for carvedilol, high doses (over 25 mg/day) were
associated with worse outcomes in patients with refractory
ascites.42–44,77,80 As already stated, the recommended dose of
carvedilol for PH is 6.25–12.5 mg/day, as increasing the dose
does not enhance the fall in portal pressure but may cause
systemic hypotension. Only the presence of concomitant arterial
hypertension in well-compensated cirrhosis – something
increasingly observed due to the increased prevalence of non-
alcoholic fatty liver disease – justify the use of higher doses ofJHEP Reports 2020carvedilol in order to correct both the arterial and the PH. A
recent study retrospectively assessed the interaction between
NSBBs and cardiac function on outcomes in patients on a
transplant waiting list (n = 584), which included 32.5% of pa-
tients with refractory ascites. The study showed that refractory
ascites and NSBB use in patients with compromised cardiac
reserve (lower left ventricular stroke work index <64.1 g.m/m2)
were associated with increased waiting list mortality in the
overall group of patients. Nevertheless, the effect of NSBBs on
mortality in the subset of patients with refractory ascites was
not addressed.82
Table 3 summarises studies on NSBB use in patients with
ascites and refractory ascites. Attention will be focussed on the
most recent and largest studies. Bossen et al. did not find
differences in survival between patients taking or not taking
NSBBs in a post hoc analysis of 1,198 patients with cirrhosis and
ascites (588 with refractory ascites).76 Patients with systolic
blood pressure <80 mmHg or creatinine >150 lmol/L were not
included in the study, which may have increased the perception
of safety of NSBBs. Bhutta et al. retrospectively analysed pro-
spective data from 717 hospitalised patients with cirrhosis and
ascites, including 366 (51%) patients with refractory ascites,
revealing no association between NSBBs and a worse
outcome.77
Aligned with the aforementioned studies, a retrospective
study of 2,419 patients studied the impact of NSBBs on in-
hospital mortality. Patients were classified according to the
presence of varices, ascites or both. In a multivariable model,
NSBBs were significantly associated with increased survival, and
indicated a survival benefit in all groups of patients, including
those with severe ascites. These results were confirmed in a
propensity score matching of a subgroup of 865 patients.39
Onali et al.79 analysed a retrospective cohort of 316 patients
with cirrhosis and ascites considered for liver transplantation
(40% with refractory ascites). Patients were classified according7vol. 2 j 100063
Table 1. Summary of the meta-analyses of randomised trials on prevention of first oesophageal variceal bleeding and rebleeding in patients with
cirrhosis treated with NSBBs.
Study
Author, year (reference)
Arms Patient and study number Main results
Prevention of first bleeding
Poynard et al. 199126 NSBB vs. control Studies: 4 trials
Patients: 589 (286 NSBB vs. 303 placebo)
Disease stage: most Child-Pugh B8;
18–37% with ascites
Bleeding: NSBB 78±3% vs. control 65±3%
(p = 0.002).
Overall mortality (2 year): NSBB 71 ±3% vs. control
68±3% survived (p = 0.34).
Bleeding-related mortality: NSBB 90±2% vs. control
and 82±3% survived (p = 0.01)
D’Amico et al. 199927 NSBB vs. placebo or non-
active treatment
NSBB vs. ISMN
NSBB + ISMN vs. NSBB







Disease stage: most Child-Pugh A and B;
4 included patients with ascites
Bleeding: NSBB vs. controls
15% vs. 25%; ARD: – 10% (95% CI – 16 to –5;
NNT = 10)
Overall mortality: ARD: –4% (95% CI –9%
to 0%)
Tripathi et al. 200789 EBL vs. NSBB Studies: 9 trials
Patients: 734 (356 EBL vs. 378 NSBB)
Disease stage: most Child-Pugh A and B;
Child-Pugh C: 10–30%
Bleeding: EBL vs. NSBB: RR 0.63 (CI 0.43–0.92),
NNT=13
Overall mortality: EBL vs. NSBB: RR 1.09
(95% CI 0.86–1.38)
Bleeding-related mortality: EBL vs. NSBB:
RR 0.71 (95% CI 0.38–1.32)
Adverse events: EBL vs. NSBB: RR 0.24
(95% CI 0.12–0.47; NNT=10)
Gluud et al. 201229 NSBB vs. EBL Studies: 12 trials
Patients: 1,504
773 NSBB vs. 731 EBL
Bleeding: EBL vs. NSBB: RR 0.67 (95% CI 0.46 to 0.98)
Overall mortality: EBL vs. NSBB: RR 1.09
(95% CI 0.92–1.30)
Bleeding-related mortality: EBL vs. NSBB:
RR 0.85 (95% CI 0.53–1.39)
Adverse advents: Both interventions were
associated with adverse events
Bai et al. 201490 NSBB±ISMN vs. EBL/SCL




3 EBL/SCL + NSBB vs. NSBB
4 ISMN + NSBB vs. NSBB
1 EBL/SCL + NSBB vs. EBL/SCL vs. NSBB vs. no
therapy; 1 EBL/SCL+ NSBB vs. EBL/SCL;
1 Spironolactone + NSBB vs. NSBB;
1 probiotics + NSBB vs. norfloxacin + NSBB vs.
NSBB
Disease stage: most Child-Pugh B7–8
Child-Pugh A6–C11
Bleeding: All combined therapies: no significant
improvement in prevention of variceal bleeding,
non–variceal bleeding
Overall mortality: no difference
Adverse events: more frequent for combined
therapy; EBL/SCL + NSBB vs. NSBB: OR 6.07 (CI
2.27–16.20; p <0.001); ISMN + NSBB vs. NSBB: OR
2.29 (CI 1.58–3.33; p <0.001)
Zacharias et al. 201891 Prevention of first
bleeding and rebleeding






4 Bleeding and rebleeding
Patients: 810
Bleeding and rebleeding: Carvedilol vs. NSBB:
RR 0.77 (95% CI 0.43–1.37)
Overall mortality: Carvedilol vs. NSBB: RR
0.86 (95% CI 0.48–1.53)
Adverse events (serious): Carvedilol vs.
NSBB: RR 0.97 (95% CI 0.67–1.42)
Sharma et al. 201934 Direct and network
meta-analysis
Studies: 32 trials
5 NSBB vs. placebo
4 EBL vs. placebo
12 EBL vs. NSBB
3 ISMN vs. NSBB
1 ISMN vs. placebo
2 EBL vs. carvedilol
2 EBL+NSBB vs. NSBB
1 EBL+NSBB vs. EBL
1 NSBB+ISMN vs. EBL
2 NSBB+ISMN vs. NSBB
Patients: 3,362
Disease stage: Child-Pugh B7 – Child-Pugh
C 11 (most Child-Pugh B 8)
Bleeding:
Carvedilol vs. placebo: OR 0.21 (95% CI
0.08–0.56)
EBL vs. placebo: OR 0.33 (95% CI 0.19–0.55)
EBL vs. NSBB: OR 0.51 (95% CI 0.34–0.76)
EBL + NSBB vs. placebo: OR 0.34 (95% CI
0.14–0.86)
NSBB vs. placebo: OR 0.64 (95% CI 0.38–1.07)
Overall mortality:
NSBB mono: OR 0.70 (95% CI 0.49–1.00)
EBL + NSBB: OR 0.49 (95% CI 0.23–1.02)
ISMN + NSBB: OR 0.44 (95% CI 0.21–0.93)
Adverse events: EBL higher serious adverse
events than NSBBs






Disease stage: Child-Pugh A (most) &
Child-Pugh C
Bleeding: Carvedilol: RR 0.74 (95% CI 0.37–1.49)
Fixed–effects model: RR 0.38 (95% CI 0.15–0.93)
All–cause mortality: RR 1.10 (95% CI 0.76–1.58)
Bleeding-related mortality: RR 1.02 (95% CI
0.34–3.10)
Adverse events: RR 4.18 (95% CI 2.19–7.95)
(continued on next page)
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4 EBL, 3 NSBB
Patients: 984
Disease stage: most Child-Pugh A and B;
Child-Pugh C: 10–49%
Bleeding: Carvedilol vs. EBL: RR 0.74
(95% CI 0.37–1.49)
Carvedilol vs. propranolol: RR 0.76
(95% CI 0.27–2.14)
Prevention of rebleeding
Bernard et al. 199753 NSBB vs. SCL Studies: 12 trials
Patients: 769
389 NSBB vs. 380 SCL
Disease stage: most Child-Pugh A and B,
Child-Pugh C: 0–35%
Rebleeding: NSBB: OR 2.3 (95% CI 1.7–3.0,
p <0.001)
Overall mortality: survival NSBB: OR 1.4
(95% CI 1.0–1.9, p = 0.04)
Bleeding-related mortality: survival NSBB:
OR 1.65 (95% CI 1.1–2.4, p = 0.01)
Adverse events: free of adverse events
higher in NSS vs. SCL: mean difference: 22%
(95% CI 6–38%, p = 0.007)
D’Amico et al. 199927 NSBB vs. placebo/no
treatment
NSBB vs. SCL
NSBB vs. NSBB + SCL
Studies: 25 trials
Patients: 1,698
Disease stage: most Child-Pugh B,
Child-Pugh C: 0–47%
Rebleeding:
NSBB vs. placebo: ARD = –21% (95% CI –30%
to –13%, NNT= 5)
NSBB vs. SCL: ARD = 7% (95% CI –2% to 17%)
NSBB vs. NSBB+SCL: ARD = 19%; (95% CI
8%–30%)
Overall mortality: NSBB: ARD = –7% (95%
CI –12% to –2%; NNT = 14)
NSBB vs. NSBB + SCL: ARD 15% (95% CI – 1% to 32%)
Adverse events: NSBB: ARD –22% (95% CI –38%
to –6; NNH = 4)
Cheung et al. 200994 EBL vs. NSSB±ISMN vs.
EBL+ NSSB±ISMN
Studies: 12 trials
6 EBL vs. NSSB±ISMN
4 EBL vs. EBL+ NSSB±ISMN
2 EBL+NSSB±ISMN vs. NSSB±ISMN
Patients: 1,381
EBL vs. NSBB: 698
Combined vs. EBL: 404
Combined vs. NSSB±ISMN: 279
Disease stage: Child-Pugh B/C 70–80%
Rebleeding: EBL vs. NSSB±ISMN: RR 1.00
(95% CI 0.73–1.37)
EBL vs. NSSB±ISMN when NSBB
dose <80 mg/d: RR 0.67 (95% CI 0.49–0.91)
EBL+ NSSB±ISMN vs. EBL; RR 0.57 (95% CI
0.31–1.08)
EBL+ NSSB±ISMN vs. NSSB±ISMN: RR 0.76
(95% CI 0.56–1.03)
Mortality: not significantly different
Adverse events: events between EBL vs.
NSSB±ISMN, but was higher with EBL+
NSSB±ISMN vs. EBL.
Funakoshi et al. 201095 EBL+ NSSB vs. EBL
SCL+NSBB vs. SCL
Studies:19 trials
4 SCL and 3 EBL
Patients: 1,483
Disease stage: most Child-Pugh B;
Child-Pugh C: 5–35%
Rebleeding: lower EBL group: OR 2.06
(95% CI 1.55–2.73, p <0.0001)
NSBB + SCL/EBL vs. only EBL/SCL reduced
rebleeding: OR 2.20 (95% CI 1.69–2.85)
Overall and Bleeding-related mortality:
No significant difference
Combination therapy lower overall mortality:
OR 1.43 (95% CI 1.03–1.98)
Adverse events (serious): NSBB: OR 2.61
(95% CI 1.60–4.40, p <0.0001)






442 combination vs. 513 monotherapy
Disease stage: most Child-Pugh B;
Child-Pugh C: 8–22%
Rebleeding: Combination therapy: RR 0.68
(95% CI 0.54–0.85, NNT: 8)
Overall mortality: Combination: RR 0.89
(95% CI 0.65–1.21)
Bleeding-related mortality: RR 0.52 (95%
CI 0.27–0.99; NNT: 33).
Adverse events: Combination: RR 1.38
(95% CI 1.13–1.68)
Adverse events (serious): RR2.02 (95%
CI 1.14–3.56)




5 EBL vs. EBL + NSBB± ISMN;
4 NSBB± ISMN vs. EBL + NSBB± ISMN
Patients: 885
476 + 409
Disease stage: most Child-Pugh B;
Child-Pugh C: 13–31%
Rebleeding: Combination vs. EBL mono:
RR 0.44 (95% CI 0.28–0.69)
Combination vs. NSBB mono: RR 0.76 (95%
CI 0.58–1.00)
Overall mortality: Combination vs. EBL
mono: RR 0.58 (95% CI 0.33–1.03)
Combination vs. NSBB mono: RR 1.24 (95%
CI 0.90–1.70)
Adverse events: Combination: rebleeding
from oesophageal ulcers increased (p = 0.01)
(continued on next page)
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Pugh A vs. B/C)
Studies: individual patient meta-analysis:
7 trials
3 EBL + NSBB vs. NSBB
4 EBL + NSBB vs. EBL
Patients: 805
389 (vs. NSBB) + 416 (vs. EBL)
Disease stage: Child-Pugh B/C: 54–89%
Rebleeding: EBL + NSBB vs. NSBB: IRR 1.00
(95% CI 0.68–1.47; p = 0.996), Child-Pugh A:
IRR 0.40 (95% CI 0.18–0.89, p = 0.025);
Child-Pugh B/C: IRR 1.36; (95% CI 0.87–2.14,
p = 0.180)
EBL + NSBB vs. EBL: IRR 0.36 (95% CI
0.21–0.59, p <0.001)
Overall mortality: EBL + NSBB vs. NSBB:
IRR 1.19 (95% CI 0.76–1.87; p = 0.449)
EBL + NSBB vs. EBL: IRR 0.50 (95% CI
0.28–0.89, p = 0.019)
Zacharias et al. 201891 Information presented
above in prevention
of first bleeding
Dwinata et al. 201992 Carvedilol vs. EBL Studies: 3 trials
Patients: 230
112 vs. 118
Disease stage: Child-Pugh B 9 (median)
Bleeding: Carvedilol: RR 1.10 (95% CI 0.75–1.61)
Overall mortality: RR 0.51 (95% CI 0.33–0.79)
Malandris et al. 201993 Carvedilol vs. propranolol
OR NSBB+ISMN OR EBL
Studies: 7 trials
3 EBL, 2 NSBBs + ISMN, 2 NSBB
Patients: 614
Disease stage most Child-Pugh B7–9
Rebleeding: Carvedilol vs. EBL: RR 1.10
(95% CI 0.75–1.61)
vs. NSBBs+ISMN: RR 1.02 (95% CI 0.70–1.51) vs.
propranolol: RR 0.39 (95% CI 0.15–1.03)
Overall mortality: compared to EBL (3 RCTs),
RR 0.51 (95% CI 0.33–0.79)
Adverse events: No significant differences for
safety compared with EBL and NSBBs
ARD, absolute risk difference; EBL, endoscopic band ligation; IRR, incidence rate ratio; ISMN, isosorbide mononitrate; NNH, number needed to harm; NNT, number needed to
treat; NSBB, non-selective beta-blocker; OR, odds ratio; RR, risk ratio; SCL, sclerotherapy.
Reviewto whether they were receiving NSBBs or not at the time of
transplant. NSBBs were associated with reduced mortality
(HR 0.511; CI 0.3–0.87; p = 0.014).
Regarding studies including carvedilol, Leithead et al. eval-
uated 322 patients with ascites listed for liver transplantation
and found a significantly lower waitlist mortality in NSBB
users.42 The subgroup of patients receiving carvedilol (medianTable 2. Appropriate dosing, targets and follow-up of available NSBBs for prev
cirrhosis.
Beta-blocker Dosing Target
Propranolol U Start 20-40 mg orally twice a day
U Increase by 20 mg twice a day steps
every 2–3 days until target; reduce
gradually if intolerant
U Maximal dosage:
- 320 mg/d (no ascites)





Nadolol U Start 20-40 mg orally once a day
U 20 mg once a day increments every
2–3 days until target; reduce gradu-
ally if intolerant
U Maximal dosage:
- 160 mg/d (no visible ascites)
- 80 mg/d (visible ascites)
Carvedilol U Start with 6.25 mg once a day
U After 3 days increase to 6.25 mg twice
a day
U Maximal dose:





JHEP Reports 2020dose 6.25 mg/d) had a mortality risk between those on pro-
pranolol and those not receiving NSBBs. Sinha R et al.44 analysed
264 patients with cirrhosis and ascites, 132 treated with car-
vedilol (median dose 12.5 mg), showing that long-term use of
carvedilol was associated with a 41% mortality reduction in
patients with mild ascites. In the subset of patients with mod-
erate or severe ascites, carvedilol did not reduce mortality, butention of first bleeding episode in patients with high-risk varices and liver
Follow-up
eart rate of 55-60 bpm
stolic pressure <90 mmHg
e tolerated
U Assess target heart rate and tolerance
at each visit
U Lifelong, assess compliance




U Lifelong, assess compliance
U No follow-up endoscopy required
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Table 3. Summary of the studies for and against NSBB use in different scenarios of advanced chronic liver disease.
Against NSBB use For NSBB use
Refractory ascites and ascites
Sersté et al. Hepatol 201011
Population: 151 (77 NSBB) patients with cirrhosis and refractory
ascites
Aetiology: 56% alcoholic cirrhosis
Dose NSBB (mean): propranolol (160 mg/d in 46.7% patients)
Follow-up: 72 days
Main result: Propranolol significantly associated with higher
mortality rate.
Limitations: High doses of Propranolol, single-centre
Strengths: Prospective cohort
Leithead et al. Gut 201542
Population: 322 (149 NSBB) patients with cirrhosis and ascites listed for
transplantation
Aetiology: 56% alcoholic cirrhosis
Dose NSBB (median): propranolol (80 mg/d) carvedilol (6.25 mg/d)
Follow-up: 72 days
Main result: NSBB use reduced significantly transplant-free
mortality
Limitations: Retrospective, transplant setting
Strengths: Propensity score matching
Sersté et al. J Hepatol 201181
Population: 10 NSBB patients with cirrhosis and refractory
ascites
Aetiology: 7 patients with alcoholic cirrhosis
Dose NSBB: 7 patients propranolol (160 mg/d)
Follow-up: 9.9 months
Main result: NSBB increase the risk of paracentesis-induced
circulatory dysfunction but not to adverse clinical outcomes
Limitations: small simple size, high doses propranolol
Strengths: Prospective
Robins et al. Hepatol 201478
Population: 114 (34 NSBB) patients with cirrhosis and ascites
Aetiology: 58% alcoholic cirrhosis
Dose NSBB (mean): propranolol (48.9 mg/d)
Follow-up: 10 months
Main result: No significant difference in mortality between propranolol
group and no propranolol group.
Limitations: Retrospective, small sample
Strengths: Appropriate doses of NSBB
Kalambokis et al. Hepatol 201696
Population: 171 (53 NSBB) patients with cirrhosis and ascites
Aetiology: 64% alcoholic cirrhosis
Dose NSBB: NR
Follow-up: 3 years
Main result: Propranolol was associated with increased
mortality
Limitations: Retrospective, unmatched
Strengths: Long-term of follow-up
Bang et al. Liver Int 201640
Population: 3,719 (743 NSBB) patients with mildly and severely
decompensated cirrhosis
Aetiology: 97% alcoholic cirrhosis
Dose NSBB (median): propranolol (97 mg/d)
Follow-up: 24 months
Main result: Significant reduced mortality was found for doses of
propranolol lower than 160 mg/d only
Limitations: Retrospective register
Strengths: Large sample size
Kim et al. Liver Transpl 201797
Population: 205 (94 NSBB) patients developed AKI in waitlist
register were matched to a case-control study
Aetiology: 48% ALD/NASH patients
Dose NSBB (median): propranolol 40 mg/d
Follow-up: 12.8 months
Main result: NSSB use in patients with ascites was associated with
increased risk of AKI
Limitations: Retrospective, many potential confounders
Strengths: Appropriate doses propranolol
Bossen et al. Hepatol 201641
Population: 1,198 (559 NSBB) cirrhosis patients with ascites
(49% refractory ascites)
Aetiology: 56% alcoholic cirrhosis
Dose NSBB: NR
Follow-up: 12 months
Main result: NSBBs did not increase significantly cirrhosis-related
mortality.
Limitations: Post hoc analysis.
Strengths: Prospective and Large sample size
Aday et al. Am J Med Sci 201639
Population: 2,419 (1,039 NSBB) cirrhosis patients with
varices or ascites
Aetiology: 44% alcoholic cirrhosis
Dose NSBB: NR
Follow-up: NR
Main result: Mortality was significantly lower in patients with cirrhosis
taking NSBB than in those not taking NSBB
Limitations: Retrospective
Strengths: Large sample size
Sinha et al. J Hepatol 201744
Population: 264 (132 NSBB) patients with cirrhosis and ascites from mild
to severe
Aetiology: 70% alcoholic cirrhosis
Dose NSBB (median): carvedilol (12.5 mg)
(continued on next page)
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Table 3 (continued)
Against NSBB use For NSBB use
Follow-up: 27.6 months
Main result: In mild ascites, use of carvedilol was associated with 43%
reduction in mortality. In severe ascites, carvedilol use did not influence
mortality
Limitations: ascites severity was based on radiology reports.
Strengths: Long-term of follow-up, carvedilol use
Onali et al. Liver Int 201779
Population: 316 (128 NSBB) patients with cirrhosis and ascites
(39% refractory ascites) on a transplant waiting list
Aetiology: 42% alcoholic cirrhosis
Dose NSBB (median): propranolol (l80 mg/d)
Follow-up (mean): 7 months
Main result: NSBB use was associated with significantly reduced
mortality
Limitations: Retrospective, short follow-up
Strengths: Well characterised population
Bhutta et al. Aliment Pharmacol Ther 201877
Population: 717 (307 NSBB) patients with cirrhosis and ascites
(51% refractory ascites)
Aetiology: 33% alcoholic cirrhosis
Dose NSBB (median): propranolol (40 mg/d), nadolol (20 mg/d) and
carvedilol (12.5 mg/d)
Follow-up (mean): 15 days
Main result: NSBB use was not associated with an increased
mortality.
Limitations: Short follow-up
Strengths: Large sample size
Tergast et al. Aliment Pharmacol Ther 201980
Population: 624 (255 NSBB) cirrhosis patients with ascites
Aetiology: 47 % alcoholic cirrhosis
Dose NSBB (median): propranolol (30 mg/d) - carvedilol
(12.5 mg/d)
Follow-up: 28 days
Main result: NSBBs were associated with a significant higher
28-day transplant-free survival.
Limitations: Retrospective, short follow-up
Strengths: Well characterized patients
Spontaneous bacterial peritonitis
Mandorfer et al. Gastroenterol 201438
Population: 182 (86 NSBB) patients at the first diagnosis of SBP








Bang et al. Liver Int 201640
Population: 361 patients with first peritonitis episode
Aetiology: 97% alcoholic cirrhosis
Dose NSBB (median): propranolol (97 mg/d)
Follow-up: 24 months
Main result: Significantly reduced mortality was observed in the
propranolol group
Limitations: Retrospective register
Strengths: Large sample size
Tergast et al. Aliment Pharmacol Ther 201980
Population: 257 patients developed SBP during hospitalisation
Aetiology: 47% alcoholic cirrhosis
Dose NSBB (median): propranolol (30 mg/d) - Carvedilol (12.5 mg/d)
Follow-up: 28 days
Main result: NSBB was associated with a higher 28-day transplant-free
survival and only patients with SBP and MAP <65 mmHg was associated
with renal impairment.
(continued on next page)
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Table 3 (continued)
Against NSBB use For NSBB use
Limitations: Retrospective, short follow-up
Strengths: Well characterized patients
Acute-on-chronic liver failure Mookerjee et al. J Hepatol 201643
Population: 349 (155 NSBB) patients with ACLF
Aetiology: 54% alcoholic cirrhosis
Follow-up: 28 days
Dose NSBB (median): propranolol (40 mg/d) - Carvedilol (12.5 mg/d)
Main result: NSBB treatment was associated with significantly reduction in
28-day mortality
Limitations: NSBB group had lower grades of ACLF
Strengths: Prospective cohort, Large sample
ACLF, acute-on-chronic liver failure; AKI, acute kidney injury; ALD, alcohol-related liver disease; HRS, hepatorenal syndrome; MAP, mean arterial pressure; NASH, non-
alcoholic steatohepatitis; NR, not reported; NSBBs, non-selective beta-blockers; PH, portal hypertension; SBP, spontaneous bacterial peritonitis.did not worsen prognosis. In the most recent study, 624 patients
with ascites were analysed retrospectively.80 Patients receiving
NSBBs had a significantly higher 28-day transplant-free survival
than patients not receiving NSBBs (p = 0.014). Results did not
differ between patients on propranolol (median 30 mg/d) and
those on carvedilol (median 12.5 mg/d). These results support
that carvedilol at low doses (6.25–12.5 mg/d) is safe in patients
with decompensated cirrhosis. In a more detailed analysis, the
beneficial effect of NSBBs on survival was attenuated in patients
with a low MAP (<82 mmHg) and was absent in patients with
ascites and a MAP <65 mmHg; moreover, the latter group had
increased rates of renal impairment. Thus, despite the benefits
of NSBBs, patients with hypotension should be closely moni-
tored and NSBB dose reduced or withdrawn if hypotension is
severe.
Three recent meta-analyses of the mostly observational
studies previously mentioned further concluded that NSBB use
is not associated with increased mortality, including patients
with mild and refractory ascites.83–85 There was significant
heterogeneity across these studies. In summary, current evi-
dence from observational studies does not support withdrawing
NSBBs in patients with ascites or refractory ascites.76–78 Indeed,
most studies observed a benefit, with increased survival in
patients with refractory ascites treated with NSBBs.39,40,75,79,80
At Baveno VI, when part of the aforementioned data was still
unavailable, it was recommended that the NSBB dose should be
reduced or discontinued in the case of hypotension (systolic
blood pressure <90 mmHg), hyponatremia (serum sodium
<130 mEq/L) or the development of acute kidney injury (AKI).22
It was further suggested that discontinuation of NSBBs should
be temporary and that they should be carefully reinstated after
resolution of the event.
Current EASL guidelines recommend that propranolol should
not exceed daily doses >80 mg/d based on observational
data(23). Although they do not recommend carvedilol in pa-
tients with ascites, several recent studies have emerged to
support its use and safety at low doses (6.25–12.5 mg/d) in
these patients.42–44,77,80 In light of the available evidence, in
patients with refractory ascites, carvedilol can probably be used
safely at low doses (6.25–12.5 mg/day), provided the patient
maintains a systolic blood pressure over 90 mmHg. Neverthe-
less, the limits both for doses and for “safe” circulatory pa-
rameters are not currently evidence based, so further
prospective studies assessing NSBB use in patients withJHEP Reports 2020decompensated liver cirrhosis are still warranted to ascertain
whether adverse effects are related to dosage or mainly depend
on haemodynamic factors.
Spontaneous bacterial peritonitis
In a retrospective study including 607 patients at their first par-
acentesis, Mandorfer et al.38 analysed 182 patients at the first
diagnosis of SBP, suggesting that NSBB use was associated with
poor outcomes in the subgroup of patients with SBP. These pa-
tients had more episodes of HRS and AKI, and decreased
transplant-free survival. However, in this study, the subset of
patients with SBP taking NSBBs also had higher total bilirubin
levels and lower arterial blood pressure, as well as including a
higher proportion of patients with Child-Pugh C cirrhosis. It is
entirely speculative to ascribeNSBB use to the increasedmortality
rate, since this could well reflect end-stage liver disease, severe
infection or a combination of different non-identified factors. In
contrast, other studies failed to confirm a worse prognosis of
patients under NSBBs.43,76,77 Bang et al.40 analysed the largest
series,with 361 patientswith SBPand reported thatNSBB usewas
associated with increased survival. Moreover, among patients
with severely decompensated cirrhosis, NSBBs were associated
with a lower risk of developing SBP. Thus, the data is controversial
and no firm conclusions can be obtained. However, it is wise to
carefully assess patients with SBP if they are receiving NSBBs and
reduce their dose or stop their administration in cases of severe
hypotension or severe AKI. Of note, NSBBs decrease the incidence
of SBP, so they should not be prohibited in patients with ascites,
even in those with previous SBP episode(s).8
Acute-on-chronic liver failure
Patients with ACLF present an inflammatory status that can
be associated with renal failure and circulatory dysfunction,
so a concern was raised with regards to NSBB use since these
patients frequently have sepsis or AKI. Nevertheless,43 a sub-
analysis of the CANONIC study with 349 hospitalised patients
with ACLF, showed that NSBB administration improved 28-day
survival in patients with ACLF. A potential mechanism could
be increased gut motility and reduced bacterial translocation
known to be caused by beta-blockade, which in turn may
decrease systemic inflammation. More recently, Tergast et al.80
reported better survival in 254 patients with ACLF under
NSBBs. NSBB use remained a positive prognostic factor after
adjusting for potential confounders in a multivariate model,13vol. 2 j 100063
Reviewwhile early interruption of NSBBs was associated with lower
28-day transplant-free survival. Consequently, there is no evi-
dence for NSBB withdrawal in ACLF.
Table 3 describes the results, strengths and limitations of
most recent studies for and against NSBB use in refractory as-
cites, SBP and ACLF in advanced cirrhosis. Most of the evidence
comes from observational studies, as no specific RCT of NSBB
use has been carried out in these scenarios. As a result, these
studies are prone to many potential biases: short follow-up
duration (median 28 days to 27 months); heterogeneous pop-
ulation (discrepant definitions for refractory ascites and AKI,
and different NSBB doses); lack of information on titration
strategy, and policy for stopping/resuming NSBBs.
Moreover, these studies have an important inherent bias
when comparing patients receiving NSBBs or not. Patients on
NSBBs tend to have more advanced cirrhosis and higher prev-
alence of high-risk varices than those not receiving NSBBs. This
bias is difficult to avoid without randomisation, despite the use
of propensity scores or multivariate analysis.86 Nevertheless,
evidence from these studies strongly suggests that NSBBs are
not absolutely contraindicated in patients with ascites, re-
fractory ascites, SBP and ACLF,76–78 and 3 independent meta-
analyses confirmed this data.83,84,87
Non-response to non-selective beta-blockers
Currently with carvedilol as an alternative to propranolol, only
a small proportion of patients remain haemodynamic non-
responders. Since measurements of HVPG are not done
routinely in clinical practice, the decision to use NSBBs is based
on its known beneficial effects and the absence ofJHEP Reports 2020contraindications. The advent of agents more effective than
propranolol, such as carvedilol, could potentially render hae-
modynamic monitoring unnecessary even in clinical trials. Non-
invasive markers to monitor beta-blocker response are still
currently unavailable.
For secondary prophylaxis, in patients receiving NSBBs plus
EBL (complemented or not with low doses of a lipophilic statin,
such as simvastatin), TIPS is the best rescue treatment. Primary
prophylaxis failures treated with either NSBBs or EBL have no
current recommended treatment option due to the lack of RCTs
in this setting. De Souza et al.88 analysed 89 patients and found
an increased risk of rebleeding and death in patients with an
index bleed while under NSBBs. These patients (clinical NSBB
non-responders) might benefit from more aggressive therapy,
such as TIPS, particularly if the patients have high-risk features,
namely, ascites or portal vein thrombosis, and an absence of
contraindications.24Conclusions
In summary, the indication to start NSBBs has expanded
recently beyond the setting of PH-associated bleeding to pre-
vention of decompensation in patients with compensated
cirrhosis. Doses must be titrated and re-evaluated in all patients,
particularly those with decompensated cirrhosis and with
deteriorating liver failure. Data from observational studies are
contradictory regarding the safety of NSBBs in patients with
refractory ascites or infection. Future RCTs should include pa-
tients with decompensated cirrhosis to assess efficacy, dose
tolerance limits, and safety.Abbreviations
ACLF, acute-on-chronic liver failure; AKI, acute kidney injury; ALD,
alcohol-related liver disease; ARD, absolute risk difference; AV, atrio-
ventricular; EBL, endoscopic band ligation; GOV, gastroesophageal
varices; HRS, hepatorenal syndrome; HVPG, hepatic venous pressure
gradient; IGV, isolated gastric varices; IRR, incidence rate ratio; ISMN,
isosorbide mononitrate; MAP, mean arterial pressure; NASH, non-alco-
holic steatohepatitis; NNH, number needed to harm; NNT, number
needed to treat; NR, not reported; NSBBs, non-selective beta-blockers;
OR, odds ratio; PH, portal hypertension; PHG, portal hypertensive gas-
tropathy; RCT, randomised controlled trials; RR, risk ratio; SBP, sponta-
neous bacterial peritonitis; SCL, sclerotherapy; TIPS, transjugular
intrahepatic portosystemic shunt.
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